Here are five points:
1. Zacks has a $20 price objective on K2M’s stock.
2. The firm also estimates a potential upside of 11.11 percent.
3. With a 50-day moving average of $16.82, K2M has a 200-day moving average of $15.37.
4. The company’s market capitalization is $758.61 million.
5. K2M’s 52-week low is $10.10 and its 52-week high is $21.67.
More articles on devices:
Fortimedix Surgical receives CE Mark approval for FMX314: 3 notes
ChoiceSpine names new vice president of biologics: 4 key notes
Zacks lowers Orthofix to ‘hold’ rating — 5 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
